YCM
REVB icon

Yakira Capital Management’s Revelation Biosciences REVB Stock Holding History

Yakira Capital Management’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Hold
0
– -$149K – 473
2021
Q4 		– Sell
-1
Closed -$2.04M – 312
2021
Q3 		$2.7M Hold
1
– – 0.42% 74
2021
Q2 		$2.68M Hold
1
– – 0.44% 57
2021
Q1 		$2.67M Hold
1
– – 0.54% 45
2020
Q4 		$2.68M Buy
+1
New +$2.02M 0.64% 42

Other funds holding REVB

Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Yakira Capital Management's REVB Position: Q1 2022 in Review

Yakira Capital Management held its Revelation Biosciences (REVB) position steady in Q1 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #473.

Yakira Capital Management first reported a position in REVB in Q4 2020 and has held it in 4 quarters since. The position peaked at $2.7M in Q3 2021. 2 funds tracked by Wall St. Rank hold REVB as of Q1 2022.

  • Yakira Capital Management held 0 shares of Revelation Biosciences worth $0 as of Q1 2022.
  • Yakira Capital Management left its Revelation Biosciences share count unchanged in Q1 2022.
  • Revelation Biosciences made up ﹤0.01% of Yakira Capital Management's portfolio in Q1 2022, its #473 holding.
  • Yakira Capital Management first reported a position in Revelation Biosciences in Q4 2020 and has held it in 4 quarters since.
  • Yakira Capital Management's Revelation Biosciences position peaked at $2.7M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Revelation Biosciences as of Q1 2022.

Based on Yakira Capital Management's 13F filing for Q1 2022, filed 12 May 2022.